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HC administration, and reached the maximal value (19.2pg/ml)
at the end of 24hours considerably exceeding that in the control
group (3pg/ml). Therefore, after immunizationwithHC, leukocytes
producedTh1, Th2andTh17cytokines,whichplay thedifferent role
in the immune response regulation. The obtained data explain the
predominant production, in mice immunized with HC, of IgG1 and
IgG2a subisotypes to the capsular polysaccharide of S. pneumoniae
14, which are connected with IL-5 and IFN production respec-
tively. IL-17 produced by CD4+IL17+ stimulates the protection from
extracellular bacteria including S. pneumoniae that was proved by
challenging immunized mice with a lethal dose of S. pneumoniae
type 14. As a result, all immunizedmice survived as comparedwith
10% survival in the control group.
Conclusion: The ability of the hexasaccharide conjugate to
stimulate production of Th1, Th2 and Th17 cytokines with the
following production of IgG antibodies to the capsular polysaccha-
ride explains its protective activity in mice after challenge with
S.pneumoniae type 14.
http://dx.doi.org/10.1016/j.ijid.2014.03.1327
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Background: Tuberculosis remains a major health problem
worldwide, and the efﬁcacy of the only available vaccine Bacille
Calmette-Guérin (BCG) varies from 0% to 80%. It is extremelyur-
gentto ﬁnd new vaccine candidates and develop novel vaccine
approaches. The disease is caused by Mycobacterium tuberculo-
sis whose preferred habitat is the host macrophage, and cellular
immune responses are important in against intracellular bacte-
rial infection. An efﬁcacious tuberculosis (TB) vaccinewill probably
need to induce both CD4+and CD8+T-cell responses speciﬁc to a
protective Mycobacterium tuberculosis antigen(s). The gene Rv1769
has been lost from BCG-Pasteur1173 in vitro subculture, and some
studies have demonstrated that it is excellent T cell antigen. To
evaluate its immunogenicity, we used the prime-boost strategy to
immunize BALB/c mice and detected its cellular immune response.
Methods&Materials: In our research, we immunized 4-5week
old pathogen-free BALB/cmalemice byDNA/DNAandDNA/protein
prime-boost vaccination strategies. Mice were killed 4, 8, 12, 16
weeks after the last boost, and we detected antibody titers in the
serum, the proliferation rate of splenocytes, percentage of CD4+
and CD8+ T cells in the splenocytes and the IFN- and IL-4 levels
in special antigen-stimulated splenocyte cultures to measure its
immunogenicity. Measurement of these data are expressed as the
mean± standard errors(S.E.). Differences among the groups were
analyzed by one-way ANOVA and differences between two groups
wereanalyzedbyPostHocTest and thedifferenceswereconsidered
statistically signiﬁcant for P <0.05.
Results: Our data suggests that our novel DNA/DNA using
Rv1769 vaccine could elicit the most long-lasting and strongest
Th1 type cellular immune responses involving CD4+ and CD8+ T
cells. This response is characterized by a strong antibody response,
the proliferation rate of splenocytes, a high percentage of CD4+
and CD8+ T cells and high levels of IFN- in antigen-stimulated
splenocyte cultures.
Conclusion: Our results provide evidence that the gene Rv1769
is a potential antigen or subunit vaccine to TB for further study, and
in the future, we would consider build an in vivo challenge model
to extend our ﬁndings to an infection/disease protection system.
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Background: We evaluated the feasibility and acceptability of
a new presentation of liquid DTP-HepB-Hib vaccine in a UnijectTM
device in Senegal and Vietnam.
Methods&Materials:We conducted306 interviews, nine focus
groupsessions, observationsof immunizationsessions (using injec-
tion into an orange), and a desk review of national programmatic
documents. Interviews were conducted with health workers, pro-
fessional representatives, andcaretakers.Weassessed the logistical
impact of UnijectTM with theWHO-developed immunization logis-
tics planning tool.
Results: Interviewees emphasizedefﬁcacy and safety as key fac-
tors for acceptability of a new device and most perceived that the
UnijectTM device represented an improvement over existing vac-
cine presentations. Compared to current presentations, UnijectTM
reducedvaccinewasteweight andvolume, including thenumberof
empty vials (from 51% in Vietnam to 68% in Senegal). By bundling
needles and syringes, UnijectTM reduced the potential for stock-
outs of one or the other. Time per vaccinated child decreased by
27%-61% depending on the setting.Each country used more than
one DTP-HepB-Hib vaccine presentation, and UnijectTM decreased
overall cold chain requirements formost butnot all of thesepresen-
tations. Informants reported thatUniject’sTM relatively lightweight
compared to traditional auto-disabled syringes should facilitate
both outreach and mobile strategies. Challenges also were identi-
ﬁed. As a novel injection device, some stakeholders may require
reassurance that UnijectTM represents contextually appropriate
technology. Vaccinator training will be required to address several
technical issues (e.g., activating the device and themotion required
for vaccine delivery) and perceptions (e.g., that the plastic reservoir
might freeze more easily and be difﬁcult to handle). A key concern
was that the UnijectTM device was used already in Senegal for con-
